Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended. Coadministration of EFV with elbasvir/grazoprevir is contraindicated [see Contraindications (4) ] because it may lead to loss of virologic response to elbasvir/grazoprevir.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended. Coadministration of EFV with elbasvir/grazoprevir is contraindicated [see Contraindications (4) ] because it may lead to loss of virologic response to elbasvir/grazoprevir.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] .
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis B antiviral agents Adefovir dipivoxil Concomitant administration of adefovir dipivoxil is not recommended.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
HMG-CoA reductase inhibitors: Atorvastatin Pravastatin Simvastatin ↓atorvastatin* ↓pravastatin* ↓simvastatin* Plasma concentrations of atorvastatin, pravastatin, and simvastatin decreased.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
7.6 Drugs without Clinically Significant Interactions No dosage adjustment is recommended when efavirenz, lamivudine and tenofovir disoproxil fumarate is administered with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, and lorazepam.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] .
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Anti-infective: Clarithromycin ↓clarithromycin* ↑14-OH metabolite* Consider alternatives to macrolide antibiotics because of the risk of QT interval prolongation.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Calcium channel blockers: Diltiazem Others (e.g., felodipine, nicardipine, nifedipine, verapamil) ↓diltiazem* ↓desacetyl diltiazem* ↓N-monodesmethyldiltiazem* ↓calcium channel blocker Diltiazem dose adjustments should be guided by clinical response (refer to the full prescribing information for diltiazem).
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
7.6 Drugs without Clinically Significant Interactions No dosage adjustment is recommended when efavirenz, lamivudine and tenofovir disoproxil fumarate is administered with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, and lorazepam.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] .
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended. Coadministration of EFV is not recommended because it may lead to reduced therapeutic effect of pibrentasvir/glecaprevir.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Antifungals: Itraconazole Ketoconazole Posaconazole ↓itraconazole* ↓hydroxyitraconazole* ↓ketoconazole ↓posaconazole* Consider alternative antifungal treatment because no dose recommendation for itraconazole or ketoconazole can be made.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Antifungals: Itraconazole Ketoconazole Posaconazole ↓itraconazole* ↓hydroxyitraconazole* ↓ketoconazole ↓posaconazole* Consider alternative antifungal treatment because no dose recommendation for itraconazole or ketoconazole can be made.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
7.6 Drugs without Clinically Significant Interactions No dosage adjustment is recommended when efavirenz, lamivudine and tenofovir disoproxil fumarate is administered with the following: aluminum/magnesium hydroxide antacids, azithromycin, cetirizine, famotidine, fluconazole, and lorazepam.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Calcium channel blockers: Diltiazem Others (e.g., felodipine, nicardipine, nifedipine, verapamil) ↓diltiazem* ↓desacetyl diltiazem* ↓N-monodesmethyldiltiazem* ↓calcium channel blocker Diltiazem dose adjustments should be guided by clinical response (refer to the full prescribing information for diltiazem).
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Calcium channel blockers: Diltiazem Others (e.g., felodipine, nicardipine, nifedipine, verapamil) ↓diltiazem* ↓desacetyl diltiazem* ↓N-monodesmethyldiltiazem* ↓calcium channel blocker Diltiazem dose adjustments should be guided by clinical response (refer to the full prescribing information for diltiazem).
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended. Coadministration of EFV is not recommended because it may lead to reduced therapeutic effect of pibrentasvir/glecaprevir.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Antifungals: Itraconazole Ketoconazole Posaconazole ↓itraconazole* ↓hydroxyitraconazole* ↓ketoconazole ↓posaconazole* Consider alternative antifungal treatment because no dose recommendation for itraconazole or ketoconazole can be made.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
HMG-CoA reductase inhibitors: Atorvastatin Pravastatin Simvastatin ↓atorvastatin* ↓pravastatin* ↓simvastatin* Plasma concentrations of atorvastatin, pravastatin, and simvastatin decreased.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended. Concomitant administration of simeprevir is not recommended.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
HMG-CoA reductase inhibitors: Atorvastatin Pravastatin Simvastatin ↓atorvastatin* ↓pravastatin* ↓simvastatin* Plasma concentrations of atorvastatin, pravastatin, and simvastatin decreased.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended. Coadministration of EFV and sofosbuvir/velpatasvir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir. Coadministration of EFV and sofosbuvir/velpatasvir/voxilaprevir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir/voxilaprevir.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
7 DRUG INTERACTIONS Efavirenz, lamivudine and tenofovir disoproxil fumarate should not be administered with other antiretroviral medications for the treatment of HIV-1 infection. ( 7.1 ) Coadministration of efavirenz, lamivudine and tenofovir disoproxil fumarate can alter the concentrations of other drugs and other drugs may alter the concentration of efavirenz, lamivudine and tenofovir disoproxil fumarate. ( 5.3 , 7 ) 7.1 Not Recommended with Other Antiretroviral Medications Efavirenz, lamivudine and tenofovir disoproxil fumarate is a complete regimen for the treatment of HIV-1 infection; therefore, it should not be administered with other antiretroviral medications for treatment of HIV-1 infection.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] .
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Some examples include, but are not limited to, acyclovir, cidofovir, ganciclovir, valacyclovir, valganciclovir, aminoglycosides (e.g., gentamicin), and high-dose or multiple NSAIDs [see Warnings and Precautions (5.4) ] .
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended. Coadministration of EFV and sofosbuvir/velpatasvir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir. Coadministration of EFV and sofosbuvir/velpatasvir/voxilaprevir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir/voxilaprevir.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate
Hepatitis C antiviral agents: Boceprevir Elbasvir/Grazoprevir Pibrentasvir/Glecaprevir Simeprevir Velpatasvir/Sofosbuvir Velpatasvir/Sofosbuvir/ Voxilaprevir Ledipasvir/Sofosbuvir ↓boceprevir* ↓elbasvir ↓grazoprevir ↓pibrentasvir ↓glecaprevir ↓simeprevir* ↔EFV ↓velpatasvir ↓velpatasvir ↓voxilaprevir ↑TDF Concomitant administration of boceprevir is not recommended. Coadministration of EFV and sofosbuvir/velpatasvir/voxilaprevir is not recommended because it may result in loss of therapeutic effect of sofosbuvir/velpatasvir/voxilaprevir.
Source: FDA drug label - efavirenz, lamivudine and tenofovir disoproxil fumarate